JP2022548568A5 - - Google Patents

Info

Publication number
JP2022548568A5
JP2022548568A5 JP2022515905A JP2022515905A JP2022548568A5 JP 2022548568 A5 JP2022548568 A5 JP 2022548568A5 JP 2022515905 A JP2022515905 A JP 2022515905A JP 2022515905 A JP2022515905 A JP 2022515905A JP 2022548568 A5 JP2022548568 A5 JP 2022548568A5
Authority
JP
Japan
Prior art keywords
alkyl
carboxamide
fluoro
cycloalkyl
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022515905A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548568A (ja
JP7763489B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050326 external-priority patent/WO2021050824A1/en
Publication of JP2022548568A publication Critical patent/JP2022548568A/ja
Publication of JP2022548568A5 publication Critical patent/JP2022548568A5/ja
Application granted granted Critical
Publication of JP7763489B2 publication Critical patent/JP7763489B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022515905A 2019-09-11 2020-09-11 Cdk阻害剤及び医薬品としてのそれらの使用 Active JP7763489B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962898839P 2019-09-11 2019-09-11
US62/898,839 2019-09-11
US202063005577P 2020-04-06 2020-04-06
US63/005,577 2020-04-06
PCT/US2020/050326 WO2021050824A1 (en) 2019-09-11 2020-09-11 Cdk inhibitors and their use as pharmaceuticals

Publications (3)

Publication Number Publication Date
JP2022548568A JP2022548568A (ja) 2022-11-21
JP2022548568A5 true JP2022548568A5 (cg-RX-API-DMAC7.html) 2023-09-15
JP7763489B2 JP7763489B2 (ja) 2025-11-04

Family

ID=74850746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515905A Active JP7763489B2 (ja) 2019-09-11 2020-09-11 Cdk阻害剤及び医薬品としてのそれらの使用

Country Status (11)

Country Link
US (3) US20220324830A1 (cg-RX-API-DMAC7.html)
EP (1) EP4028005A4 (cg-RX-API-DMAC7.html)
JP (1) JP7763489B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220079851A (cg-RX-API-DMAC7.html)
CN (1) CN114786673A (cg-RX-API-DMAC7.html)
AU (1) AU2020345950A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022004327A2 (cg-RX-API-DMAC7.html)
CA (1) CA3153531A1 (cg-RX-API-DMAC7.html)
IL (1) IL291191A (cg-RX-API-DMAC7.html)
MX (1) MX2022002946A (cg-RX-API-DMAC7.html)
WO (1) WO2021050824A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020345950A1 (en) 2019-09-11 2022-03-31 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
AU2020401999B2 (en) * 2019-12-09 2024-01-18 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Compound as cyclin-dependent kinase 9 inhibitor and use thereof
CN114605390B (zh) * 2020-12-04 2024-08-16 上海凌达生物医药有限公司 具有cdk激酶抑制活性的化合物、其药物组合物和用途
CN115381824B (zh) * 2021-05-24 2024-11-05 石药集团中奇制药技术(石家庄)有限公司 周期蛋白依赖性激酶9抑制剂的用途
WO2022247785A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术(石家庄)有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
US20230144528A1 (en) * 2021-09-30 2023-05-11 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
AU2022362075A1 (en) * 2021-10-14 2024-05-09 Prelude Therapeutics Incorporated Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof
WO2025076115A1 (en) * 2023-10-02 2025-04-10 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
WO2025189114A1 (en) 2024-03-08 2025-09-12 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
WO2026024933A1 (en) * 2024-07-24 2026-01-29 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
CN119638640A (zh) * 2024-12-10 2025-03-18 杭州亦宁医药技术有限公司 一种5-溴-2-甲基-3-异丙基-吲唑的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070354A2 (en) * 2006-10-31 2008-06-12 Smithkline Beecham Corporation 5- and 6- substituted benzimidazole thiophene compounds
CA2719059C (en) 2008-03-27 2016-05-17 Nestec S.A. Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates
US8435980B2 (en) * 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
US9440952B2 (en) * 2013-03-04 2016-09-13 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
TW201444820A (zh) 2013-03-13 2014-12-01 Abbvie Inc 吡啶cdk9激酶抑制劑
WO2015108881A1 (en) * 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TN2016000270A1 (en) * 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
US10035777B2 (en) 2014-08-05 2018-07-31 Bristol-Myers Squibb Company Heterocyclic kinase inhibitors
WO2016197078A1 (en) * 2015-06-05 2016-12-08 Syros Pharmaceuticals, Inc. Compounds for the modulation of myc activity
TR201909286T4 (tr) * 2015-06-29 2019-07-22 Astrazeneca Ab CDK9 inhibitörleri olarak polisiklik amid türevleri.
US10815432B2 (en) 2015-09-22 2020-10-27 Hindustan Petroleum Corporation Limited Additive and a catalyst composition comprising the additive for FCC process
FR3041639B1 (fr) 2015-09-30 2019-01-25 Les Laboratoires Servier NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
CN107641118B (zh) * 2016-07-22 2020-11-06 爱科诺生物医药股份有限公司 具有细胞坏死抑制活性的化合物及其组合物和应用
AU2020345950A1 (en) * 2019-09-11 2022-03-31 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
AU2020401999B2 (en) * 2019-12-09 2024-01-18 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Compound as cyclin-dependent kinase 9 inhibitor and use thereof
US20230265083A1 (en) * 2020-08-10 2023-08-24 Prelude Therapeutics Incorporated Heterocycle CDK Inhibitors And Their Use Thereof
EP4214213A1 (en) * 2020-09-21 2023-07-26 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
IL316942A (en) * 2020-12-18 2025-01-01 Prelude Therapeutics Inc CDK inhibitors and their use as drugs
US20230144528A1 (en) * 2021-09-30 2023-05-11 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
AU2022362075A1 (en) * 2021-10-14 2024-05-09 Prelude Therapeutics Incorporated Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof
WO2025076115A1 (en) * 2023-10-02 2025-04-10 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals

Similar Documents

Publication Publication Date Title
CA2900855C (en) Aminopyrimidinyl compounds
JP2019504901A5 (cg-RX-API-DMAC7.html)
HRP20210949T1 (hr) Spojevi i sastavi za moduliranje aktivnosti egfr mutant kinaze
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
HRP20240994T1 (hr) Spoj inhibitora jak i njegova uporaba
HRP20180335T1 (hr) Kondenzirani derivati imidazola korisni kao ido inhibitori
JP2017530185A5 (cg-RX-API-DMAC7.html)
HRP20120656T1 (hr) Derivati indazolil amida za liječenje poremećaja posredovanih glukokortikoidnim receptorom
JP2019505541A5 (cg-RX-API-DMAC7.html)
HRP20121069T1 (hr) Supstituirani derivati amida kao inhibitori protein kinaze
IL276031B2 (en) oxazine monoacylglycerol lipase (magl) inhibitors
JP2014139226A5 (cg-RX-API-DMAC7.html)
HRP20130106T1 (hr) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
JPWO2020017587A5 (cg-RX-API-DMAC7.html)
HRP20140814T1 (hr) Inhibitori jak2 i njihova uporaba za lijeäśenje mijeloproliferativnih bolesti i karcinoma
SI2961736T1 (en) Histone demethylase inhibitors
JP2018522847A5 (cg-RX-API-DMAC7.html)
RU2014131707A (ru) Соединения пиридазинамида и их применение в качестве ингибиторов тирозинкиназы селезенки (syk)
JP2016517878A5 (cg-RX-API-DMAC7.html)
RU2348628C2 (ru) Замещенные циклопропильной группой оксазолидиноновые антибиотики и их производные
JP2013538801A5 (cg-RX-API-DMAC7.html)
JP2014531449A5 (cg-RX-API-DMAC7.html)
HRP20110015T1 (hr) DERIVATI IMIDAZO[1,2-a]PIRIDIN-2-KARBOKSAMIDA, NJIHOVO DOBIVANJE I NJIHOVA UPOTREBA U TERAPIJI
RU2009142431A (ru) Производные триазолопиридинкарбоксамидов и триазолопиримидинкарбоксамидов, их получение и их применение в терапии
JP2021515004A5 (cg-RX-API-DMAC7.html)